Skip to Main Content

Paper Details

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
Clin Cancer Res
73
2019
AR, AR-A, Androgen, Androgen Receptor, Cancer, ERG, PARP, Primary Prostate Cancer, androgen, androgen receptor, basal, basal subtype, docetaxel, localized prostate cancer, low, mCRPC, metastatic castration-resistant prostate cancer, patients, platinum, primary prostate cancer, tumors
Author NameAffiliation
Daniel E SprattUniversity of Michigan ann arbor
Mohammed AlshalalfaUniversity of California san francisco
Adam B WeinerFeinberg School of Medicine, Northwestern University
Rohit MehraUniversity of Michigan ann arbor
Brandon A MahalDana-Farber/Brigham and Women's Cancer Center and Harvard Medical School
Yang Liu
Stephen J FreedlandCedars-Sinai Medical Center
Robert Jeffrey KarnesMayo Clinic
Sheila WeinmannCenter for Health Research, Kaiser Permanente Northwest
Elai Davicioni
Ashley E Ross
Robert B DenSidney Kimmel Medical College, Thomas Jefferson University
Paul L NguyenDana-Farber/Brigham and Women's Cancer Center and Harvard Medical School
Felix Y FengUniversity of California san francisco
Tamara L LotanJohns Hopkins School of Medicine
Arul M ChinnaiyanUniversity of Michigan ann arbor
Arul M ChinnaiyanUniversity of Michigan ann arbor
Edward M SchaefferFeinberg School of Medicine, Northwestern University
  • 1 - 18

Datasets

Release 1.2